The appetite for risk in orthopedic medical device companies evolves dramatically with their size—reflecting changes in resources, priorities, and stakeholder pressures.In my last startup, the CEO hammered it home: our only real advantage over the Big Orthos was the freedom to take extreme risks every single week.
Here's how that appetite shifts as companies grow:
1. Startup Phase (~5 employees, zero to minimal sales)
Pure survival mode. With no revenue cushion, bold innovation is non-negotiable. Tiny teams chase moonshot implants or instruments, swinging for high-risk/high-reward breakthroughs to grab investor attention and carve a niche. Resources are scarce, so they bet big—or die.
2. Small Enterprise (~50 employees, emerging revenue)
Risk becomes more calculated. Steady sales provide breathing room, allowing a split focus: supporting current products to build trust while pushing R&D for portfolio expansion. Experimentation continues, but now with a safety net to avoid total collapse.
3. Mid-Sized Firm (~300 employees, solid single-digit growth)
Optimization takes center stage. Protecting market share tempers boldness. New projects face rigorous scrutiny to safeguard existin...
